Linde India Ltd
Linde India Limited, a subsidiary of BOC Group,UK (owns 75% stake in the co), is primarily engaged in manufacture of industrial and medical gases and construction of cryogenic and non cryogenic air separation plants.[1]
- Market Cap ₹ 58,523 Cr.
- Current Price ₹ 6,865
- High / Low ₹ 8,049 / 5,539
- Stock P/E 118
- Book Value ₹ 509
- Dividend Yield 0.06 %
- ROCE 18.2 %
- ROE 13.8 %
- Face Value ₹ 10.0
Pros
- Company has been maintaining a healthy dividend payout of 21.8%
Cons
- Stock is trading at 13.5 times its book value
- The company has delivered a poor sales growth of 11.5% over past five years.
- Company has a low return on equity of 13.0% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Industrial Gases
Part of BSE 500 BSE 200 BSE Dollex 200 Nifty 500 Nifty MNC
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2023 15m | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,491 | 1,567 | 1,825 | 2,033 | 2,192 | 1,762 | 1,471 | 2,112 | 3,136 | 2,769 | 2,485 | 2,531 | 2,733 | |
| Sales growth | +4% | +5% | +17% | +11% | +8% | -20% | -16% | +44% | +48% | -12% | -10% | +2% | +13% |
| 1,214 | 1,337 | 1,539 | 1,705 | 1,866 | 1,347 | 1,096 | 1,564 | 2,371 | 2,066 | 1,720 | 1,622 | 1,871 | |
| Operating Profit | 277 | 230 | 287 | 328 | 326 | 415 | 375 | 548 | 765 | 702 | 765 | 909 | 862 |
| OPM % | 19% | 15% | 16% | 16% | 15% | 24% | 25% | 26% | 24% | 25% | 31% | 36% | 32% |
| 11 | 22 | 34 | 11 | 23 | 862 | 44 | 348 | 109 | 77 | 68 | 67 | 72 | |
| Interest | 103 | 90 | 116 | 116 | 103 | 86 | 6 | 3 | 6 | 7 | 13 | 14 | 30 |
| Depreciation | 181 | 162 | 195 | 206 | 199 | 177 | 176 | 181 | 253 | 201 | 214 | 235 | 252 |
| Profit before tax | 4 | 1 | 10 | 16 | 47 | 1,013 | 236 | 711 | 614 | 571 | 606 | 727 | 652 |
| Tax % | -51% | -4,164% | -31% | -17% | 29% | 28% | 34% | 28% | 13% | 25% | 26% | 24% | |
| 5 | 23 | 13 | 19 | 33 | 727 | 156 | 514 | 536 | 426 | 448 | 551 | 495 | |
| EPS in Rs | 0.63 | 2.75 | 1.57 | 2.22 | 3.93 | 85.27 | 18.24 | 60.26 | 62.82 | 49.99 | 52.51 | 64.59 | 58.01 |
| Dividend Payout % | 237% | 27% | 48% | 45% | 38% | 12% | 16% | 22% | 19% | 24% | 23% | 19% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 11% |
| 3 Years: | -7% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 41% |
| 5 Years: | 30% |
| 3 Years: | 1% |
| TTM: | -2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 35% |
| 5 Years: | 22% |
| 3 Years: | 4% |
| 1 Year: | 21% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 13% |
| Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 |
| Reserves | 1,304 | 1,307 | 1,310 | 1,322 | 1,342 | 2,052 | 2,118 | 2,606 | 3,029 | 3,349 | 3,694 | 4,142 | 4,259 |
| 1,564 | 1,388 | 1,445 | 1,282 | 1,199 | 108 | 7 | 24 | 22 | 21 | 42 | 79 | 1,026 | |
| 926 | 883 | 722 | 680 | 759 | 970 | 1,048 | 1,287 | 1,246 | 1,324 | 1,289 | 1,463 | 1,352 | |
| Total Liabilities | 3,880 | 3,664 | 3,563 | 3,369 | 3,385 | 3,215 | 3,259 | 4,003 | 4,382 | 4,780 | 5,110 | 5,769 | 6,722 |
| 2,201 | 2,158 | 2,573 | 2,498 | 2,162 | 2,035 | 1,989 | 1,869 | 1,762 | 1,822 | 1,925 | 2,093 | 3,553 | |
| CWIP | 356 | 577 | 80 | 36 | 44 | 53 | 17 | 68 | 225 | 483 | 975 | 1,343 | 1,091 |
| Investments | 15 | 15 | 15 | 15 | 0 | 0 | 2 | 2 | 16 | 27 | 42 | 43 | 55 |
| 1,308 | 915 | 895 | 821 | 1,179 | 1,127 | 1,251 | 2,064 | 2,378 | 2,448 | 2,168 | 2,291 | 2,023 | |
| Total Assets | 3,880 | 3,664 | 3,563 | 3,369 | 3,385 | 3,215 | 3,259 | 4,003 | 4,382 | 4,780 | 5,110 | 5,769 | 6,722 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 271 | 242 | 293 | 252 | 376 | 327 | 339 | 589 | 629 | 437 | 584 | 786 | |
| -264 | -58 | -128 | -59 | -73 | 981 | -54 | 98 | -306 | -539 | -1,305 | -705 | |
| -8 | -222 | -80 | -261 | -216 | -1,193 | -201 | -28 | -119 | -105 | -112 | -116 | |
| Net Cash Flow | -1 | -37 | 85 | -68 | 87 | 115 | 84 | 659 | 203 | -208 | -833 | -35 |
| Free Cash Flow | 5 | 181 | 160 | 184 | 286 | 251 | 271 | 454 | 280 | -127 | -739 | 25 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 106% | 101% | 104% | 79% | 118% | 82% | 98% | 121% | 107% | 84% | 101% | 109% |
Ratios
Standalone / View Consolidated
| Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 75 | 78 | 71 | 63 | 61 | 79 | 101 | 73 | 47 | 63 | 57 | 73 |
| Inventory Days | 153 | 141 | 102 | 91 | 66 | 57 | 72 | 37 | 22 | 32 | 69 | 79 |
| Days Payable | 541 | 466 | 447 | 348 | 293 | 327 | 477 | 312 | 156 | 235 | 349 | 370 |
| Cash Conversion Cycle | -313 | -247 | -274 | -194 | -166 | -190 | -303 | -202 | -87 | -139 | -224 | -217 |
| Working Capital Days | -81 | 16 | -70 | -69 | -81 | -22 | 6 | -3 | -9 | -11 | -29 | -40 |
| ROCE % | 3% | 3% | 4% | 5% | 6% | 11% | 10% | 17% | 21% | 17% | 17% | 18% |
Insights
In beta| Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gases Revenue Share % |
|
|||||||||||
| Top 2 Customer Revenue Share % |
||||||||||||
| Number of Operating Plants count |
||||||||||||
| PED Order Book INR million |
||||||||||||
| Medical Oxygen Daily Delivery TPD |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Acquisition
- Linde India approved acquisition of Airtech Cryogenic Gases for Rs. 111.20 crore on 13 November 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Our letter no. Sect/88 dated 5 November 2026 enclosing therewith copies of newspaper publication regarding extract of consolidated financial results of the Company ....
-
Updates On Outcome Of Board Meeting Held On 3 November 2026
- Board approved Q2 and H1 FY2026-27 standalone and consolidated results on 3 November 2026.
-
Board Meeting Outcome for Updates On Outcome Of Board Meeting Held On 3 November 2026
- Board approved Q2 and H1 FY2027 results on 3 November 2026; revenue rose, profit increased.
-
Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended 30 September 2026
- Board meeting on 3 November 2026 to approve Q2 and half-year FY2026-27 results.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Business Segments:[1]
a) Gases, Related Products & Services (78% in Q1 FY27 vs 87% in Q1 FY26):[2]
The company supplies industrial and specialty gases such as oxygen, nitrogen, and argon through onsite pipeline systems, bulk liquid distribution networks, and packaged gas solutions. Its healthcare portfolio caters to hospitals and healthcare providers by offering medical gases and associated solutions.
b) Project Engineering Division (22% in Q1 FY26 vs 13% in Q1 FY26):[3]
The company offers turnkey engineering solutions for cryogenic gases, including the design, supply, installation, and commissioning of medium- to large-sized Air Separation Units (ASUs), nitrogen plants, and gas distribution networks. The division also manufactures cryogenic equipment such as distillation columns, cold boxes, cryogenic vessels,
and vaporizers for both internal use and
external customers.